Jack W. Callicutt
2019
In 2019, Jack W. Callicutt earned a total compensation of $778.1K as Chief Financial Officer at Galectin Therapeutics, a 39% decrease compared to previous year.
Compensation breakdown
| Bonus | $233,450 |
|---|---|
| Option Awards | $191,568 |
| Salary | $285,000 |
| Other | $68,105 |
| Total | $778,123 |
Callicutt received $285K in salary, accounting for 37% of the total pay in 2019.
Callicutt also received $233.5K in bonus, $191.6K in option awards and $68.1K in other compensation.
Rankings
In 2019, Jack W. Callicutt's compensation ranked 10,333rd out of 13,971 executives tracked by ExecPay. In other words, Callicutt earned more than 26.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,333 out of 13,971 | 26th |
Division Manufacturing | 4,182 out of 5,701 | 27th |
Major group Chemicals And Allied Products | 1,607 out of 2,200 | 27th |
Industry group Drugs | 1,376 out of 1,886 | 27th |
Industry Pharmaceutical Preparations | 1,025 out of 1,398 | 27th |
Source: SEC filing on October 19, 2020.
Callicutt's colleagues
We found one more compensation record of an executive who worked with Jack W. Callicutt at Galectin Therapeutics in 2019.
2019
Harold Shlevin
Galectin Therapeutics
Chief Executive Officer
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020